First-in-Human Phase 1b/2a Trial Shows Safety with MEK 1/2 Inhibitor EDV2209 as A Novel Treatment for Spontaneous Subarachnoid Hemorrhage
Translational Stroke Research · 2026-12 · 17 (6)
DOI: 10.1007/s12975-026-01504-y ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Translational Stroke Research, online erschienen am 30.10.2026. Verfasst von Emelie P Fungbrant und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, MAP Kinase Kinase 2, MAP Kinase Kinase 1, Protein Kinase Inhibitors. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edvince AB, Lund, Sweden, Funding was provided by Edvince AB, Lund, Sweden, Karolinska Institute.
Abstract (Originalsprache)
We report findings from a Phase 1/2a clinical trial (EUCT No. 2024-514590-22-00, STOP-DCI), an interventional, randomized, double-blind, placebo-controlled, multiple ascending-dose, first-in-human trial to determine safety and evaluate clinical outcome for the MEK 1/2 inhibitor EDV2209 in patients with severe spontaneous subarachnoid hemorrhage (SAH). In Phase 1b ( N = 11), three cohorts received a single intracerebral ventricular (ICV) bolus (8.55 µg, 17–28.5 µg). In Phase 2a ( N = 16), two cohorts were given three ICV injections of 28.5 µg EDV2209 or placebo over 18 h, beginning within 8 h of SAH onset. The study found an equal distribution of adverse events between treatment and placebo with no treatment-associated safety concerns. Outcomes and mortality were as expected or better for patients with severe SAH in the patients treated with EDV2209. Pharmacokinetics were reproducibly stable in the CSF with no detectable levels of EDV2209 in plasma. Treatment with EDV2209 was considered safe and was interpreted to provide potential benefit for improving patient outcome following severe SAH. These results provide a rationale to continue with a Phase 2b / 3 study powered to determine efficacy as well as safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Neurosurgery, Copenhagen University Hospital- Rigshospitalet, Copenhagen, Denmark.
- Department of Neuroanaesthesiology, Copenhagen University Hospital- Rigshospitalet, Copenhagen, Denmark.
- Department of Neurosurgery, Odense University Hospital, Odense, Denmark.
- Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden.
- Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, United States of America.
Förderung
- Edvince AB, Lund, Sweden
- Funding was provided by Edvince AB, Lund, Sweden
- Karolinska Institute
Zitieren
APA
Fungbrant, E. P., Bömers, J. P., Jensen, H. R., Møller, K., Nielsen, T. H., Kinnman, E., Krause, D. N., Mathiesen, T., & Edvinsson, L. (2026). First-in-Human Phase 1b/2a Trial Shows Safety with MEK 1/2 Inhibitor EDV2209 as A Novel Treatment for Spontaneous Subarachnoid Hemorrhage. Translational Stroke Research, 17(6). https://doi.org/10.1007/s12975-026-01504-y
Vancouver
Fungbrant EP, Bömers JP, Jensen HR, Møller K, Nielsen TH, Kinnman E, et al. First-in-Human Phase 1b/2a Trial Shows Safety with MEK 1/2 Inhibitor EDV2209 as A Novel Treatment for Spontaneous Subarachnoid Hemorrhage. Translational Stroke Research. 2026;17(6). doi:10.1007/s12975-026-01504-y
BibTeX
@article{Fungbrant2026,
author = {Fungbrant, Emelie P and Bömers, Jesper Peter and Jensen, Helene Ravnholt and Møller, Kirsten and Nielsen, Troels Halfeld and Kinnman, Erik and Krause, Diana N and Mathiesen, Tiit and Edvinsson, Lars},
title = {First-in-Human Phase 1b/2a Trial Shows Safety with MEK 1/2 Inhibitor EDV2209 as A Novel Treatment for Spontaneous Subarachnoid Hemorrhage},
journal = {Translational Stroke Research},
year = {2026},
volume = {17},
number = {6},
doi = {10.1007/s12975-026-01504-y}
}
EUVIMED